Company News
Shaftesbury plans £265m placing to fund acquisitions
Shaftesbury has announced plans for a placing of up to 27. 86m new ordinary shares at 952p each, representing around 9. 98% of the company and raising gross proceeds of up to £265m to fund a number of acquisitions.
HarbourVest renews undrawn $500m credit facility
Closed-end investment company HarbourVest Global Private Equity has announced the successful renewal of its existing $500m multi-currency credit facility with Lloyds Bank and Credit Suisse.
Insurance challenges, Monarch collapse hit Saga
Specialist in products and services for life after 50, Saga, issued a trading update for the period from 1 August to 5 December on Wednesday, reporting that growth in underlying profit before tax was expected to be between 1% and 2% for the year to 31 January 2018.
James Fisher buys Lancashire-based EDS for up to £14.6m
Marine engineering services group James Fisher has bought Lancashire-based EDS, which provides a complete range of high voltage engineering services to the renewables industry, for up to £14. 6m.
EasyJet traffic rises 8% in November, announces new German domestic routes
Budget airline EasyJet reported an 8. 1% jump in passenger numbers in November on Wednesday as the load factor ticked higher.
Swiss Re to take on Legal & General mature savings unit
Legal & General Group has reached agreement to sell its mature savings business to the ReAssure division of Swiss Re for £650m, it announced on Wednesday.
Smith & Nephew buys Rotation Medical for up to $210m
Medical technology business Smith & Nephew has completed the acquisition of Rotation Medical Inc, which develops novel tissue regeneration technology for shoulder rotator cuff repair, for $125m, with a further $85m due over the next five years contingent on financial performance.
GlaxoSmithKline releases positive data on Shingrix efficacy
GlaxoSmithKline released new data from a Phase III clinical study on Wednesday, which it said supports the safety and efficacy of Shingrix in preventing shingles when given to adults 18 years and above shortly after undergoing autologous haematopoietic stem cell transplant.